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Abstract 
Background: Cystoid macular edema associated with latanoprost administration has been reported in patients after 
complicated cataract surgery with coexisting risk factors. We present the first case of preservative free latanoprost 
associated cystoid macular edema that occurred many months after uncomplicated cataract surgery.
Case presentation: A 65-year old Caucasian female presented in the Outpatients Clinic complaining of reduced 
vision and metamorphopsia in the right eye. She had undergone uneventful phacoemulsification 19 months ago in 
the right eye and was under treatment with preservative free latanoprost eye drops for the last 7 months for ocular 
hypertension. Her remaining medical and ocular history were otherwise unremarkable. Cystoid macular edema with 
serous retinal detachment was diagnosed in the right eye using optical coherence tomography and fluorescein angi-
ography. Latanoprost was discontinued and brinzolamide and nepafenac eye drops were administered in the right 
eye. Two months later, cystoid macular edema completely resolved with restoration of visual acuity. Nepafenac eye 
drops were administered for another 2 months. Eight months after latanoprost cessation optical coherence demon-
strated no sign of cystoid macular edema whereas a subtle epiretinal membrane was noted.
Conclusions: Cystoid macular edema may potentially occur in patients receiving preservative free latanoprost. 
More interestingly, in our case it was diagnosed in a patient with a long standing pseudophakia after uncomplicated 
phacoemulsification. No obvious risk factor for macular edema development was recognized. Prompt diagnosis and 
latanoprost discontinuation resulted in complete resolution of the cystoid macular edema and functional restoration 
of the eye.
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Background
Latanoprost (LP) is a phenyl-substituted prostaglan-
din analogue (PGA) that has become the most popular 
antiglaucoma medication for the treatment of primary 
open-angle glaucoma and ocular hypertension. Adminis-
tered topically, LP lowers the intraocular pressure (IOP) 
presumably by increasing the uveoscleral outflow. The 
adverse effects of LP have been relatively mild and topi-
cal, mainly consisting of hypertrichosis, increased eyelash 
pigmentation, topical irritation, conjunctival hyperemia, 
superficial punctate keratopathy, and increased iris pig-
mentation while cystoid macular edema (CME) is consid-
ered a rare adverse effect [1].
There are several case reports presenting CME in early 
postoperative pseudophakias in eyes that are adminis-
tered topical PGAs like LP, travoprost, bimatoprost, or 
unoprostone [2]. In the majority of these cases widely 
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accepted risk factors that may potentially alter the 
blood–retinal barrier (BRB) and increase the risk of CME 
coexisted. These conditions include aphakia, complicated 
cataract surgery, vitreous loss, excessive intraoperative 
manipulations such as mechanical pupil stretch or iris 
prolapse during surgery, absent or ruptured posterior 
capsule, the presence of an anterior chamber intraocular 
lens, filtering or other glaucoma operations and intraocu-
lar surgeries, epiretinal membrane, history of uveitis or 
prior CME, retinal inflammatory or vascular disease like 
diabetes mellitus etc. [3, 4].
Latanoprost-related CME after uncomplicated phaco-
emulsification in absence of any systemic or ocular risk 
factors for developing CME is uncommon. There are 
reports of CME in six eyes treated with LP where the 
only recognized risk factor was previous uncomplicated 
cataract surgery [3]. However, details about these cases 
are lacking and, as the authors state, risk factors may 
be underestimated since five of them were spontaneous 
reports and one occurred during a phase III clinical trial. 
Yeh et  al. report four cases where CME was clinically 
diagnosed 1 month after uneventful phacoemulsification, 
while LP was not discontinued perioperatively [4]. There-
after, ten cases of PGA associated CME after uneventful 
cataract surgery in patients without known risk factors 
are described in more detail (Table 1) [5–11].
In the following report we describe a patient with a 
history of uncomplicated phacoemulsification surgery 
19 months ago who developed CME 7 months after ini-
tiation of preservative free LP.
Case presentation
A 65-year old Caucasian female presented in the Out-
patients Clinic complaining of gradually reduced vision 
and metamorphopsia in the right eye (OD). Patient’s 
medical and ocular history were unremarkable. She had 
undergone uncomplicated cataract surgery with poste-
rior chamber intraocular lens (IOL) implantation in OD 
19  months ago and was on treatment with preservative 
free LP 0.005% (Monoprost 50  µg/ml, Thea, Clermont-
Ferrand, France) every night in both eyes (OU) for the 
last 7  months due to ocular hypertension. At the time 
that LP ophthalmic solution was initiated patient’s 
best-corrected visual acuity (BCVA) was 20/20 OU and 
intraocular pressure (IOP) was 24  mm Hg OU while 
Optical Coherence Tomography (OCT), conducted as 
baseline examination, was normal (Fig. 1a).
On admission, ocular examination disclosed BCVA 
20/30 in OD and 20/20 in OS. Slit lamp examination of 
OD revealed IOL in the capsular bag with intact pos-
terior capsule with no evidence of intraocular inflam-
mation or any other pathology such as ruptured 
posterior capsule. Slit lamp examination of OS was 
normal. Intraocular pressure was 14  mmHg OU. Fun-
dus examination revealed a slight decrease in the foveal 
reflectivity OD indicative of CME whereas no pathology 
was observed in OS. Optical coherence tomography in 
OD confirmed the diagnosis of CME demonstrating well-
defined, intraretinal cystic areas of low reflectivity in the 
macula, mainly in the outer plexiform and inner nuclear 
layers of the retina, with serous retinal detachment (SRD) 
(Fig.  1b). Fluorescein angiography (FA) in OD revealed 
a petaloid leakage from the perifoveal retinal capillaries 
during the late phases without staining of the optic disc, 
while multiple areas of subtle fluorescein leakage was 
noted throughout the retina (Fig. 2a). No leakage or any 
other pathology was observed in the OS (Fig. 2b).
Latanoprost was discontinued and was replaced with 
brinzolamide eye drops 1% b.i.d (Azopt 10 mg/ml, Alcon 
Laboratories Ltd., Hertfordshire, UK) OU. Nepafenac 
eye drops (Nevanac, 1  mg/ml, Alcon Laboratories Ltd., 
Hertfordshire, UK) t.i.d. were administered in OD. One 
month later, BCVA was restored to 20/20 in OD, meta-
morphopsia disappeared, and OCT demonstrated sub-
sidence of CME with a single remaining intraretinal 
cyst. Two months after LP discontinuation, OCT dem-
onstrated complete resolution of CME whereas a subtle 
epiretinal membrane was noted (Fig.  1c). At that time 
BCVA was 20/20 OU and IOP 17  mmHg in OD and 
18 mmHg in OS. Nepafenac eye drops were administered 
for additional 2  months. Patient was examined every 
month thereafter. Eight months after LP cessation patient 
had BCVA 20/20 OU and IOP 18 mmHg OU, while she 
remained on brinzolamide eye drops b.i.d. OU. Optical 
coherence tomography demonstrated no sign of CME.
Discussion
We describe the occurrence of CME with SRD in a 
pseudophakic patient 7  months after LP initiation and 
19  months after uneventful phacoemulsification cata-
ract extraction with posterior chamber IOL implant 
and intact posterior capsule. The diagnosis of CME was 
established with the characteristic OCT and FA findings, 
whereas no other possible causes of CME could be recog-
nized in that eye. Although the patient was pseudophakic 
in OD for 19  months, there was no evidence of pseu-
dophakic CME before LP initiation as it was indicated 
by clinical examination and a reference OCT, while CME 
was developed only in the pseudophakic eye treated with 
LP. Cystoid macular edema resolved with LP discontinua-
tion and administration of nepafenac eye drops.
The exact mechanism by which LP may cause CME 
remains unclear. While LP does not seem to exhibit 
direct vasoactive or inflammatory properties, it is 
assumed that in early postoperative pseudophakias, LP 
affects the wound healing process of lens epithelial cells 
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accelerating the biosynthesis of endogenous prostaglan-
dins and other inflammatory mediators that eventually 
enhance disruption the blood-aqueous-barrier resulting 
in increase of incidence of angiographic CME [3, 12]. It 
is proposed that several risk factors such as complicated 
cataract surgery, vitreous loss, absent or ruptured poste-
rior capsule render some eyes more prone to develop PG 
related CME [3, 4]. However, the vast majority of pseu-
dophakic eyes treated with PGAs, even those with addi-
tional risk factors, do not develop CME [3]. Interestingly, 
our case does not have an obvious risk factor for develop-
ing CME except from the pseudophakic status itself.
Reviewing the cases in Table  1, four cases have a 
common feature which is pseudoexfoliative glaucoma 
[6, 10]. Pseudoexfoliation could be recognized as an 
independent risk factor since it results in abnormal 
blood-aqueous barrier predisposing to CME after phaco-
emulsification [13]. In two other cases CME occurred 
after uncomplicated extracapsular cataract extraction 
[6, 8]. In these cases someone could argue that the intra-
operative manipulations during extracapsular cataract 
extraction could pose a risk factor that could interfere 
with the BRB integrity [14]. Of the remaining cases there 
are three cases of PGA associated CME where PGA had 
been already administered before surgery without being 
discontinued perioperatively and during the early post-
operative period when the BRB is unstable [7, 9, 11].
In our case and in the case reported by Costagliola 
et  al. [5] the CME occurred in eyes with long standing 
pseudophakias. In the case reported by Costagliola et al. 
[5] LP was prescribed 24-month after phacoemulsifica-
tion and CME was diagnosed 5 days after initiation of LP 
treatment. Our patient had never received any antiglau-
coma treatment until 12 months after surgery. While one 
could expect restoration of BRB in eyes with long stand-
ing pseudophakias, these two cases imply that blood-
ocular barrier might remain fragile to LP several months 
after uncomplicated phacoemulsification even in eyes 
without other risk factors for BRB disruption.
Interestingly, it has been proposed that the main cause 
of CME in early postoperative pseudophakias is not LP, 
but rather the benzalkonium chloride, added as preserva-
tive in many antiglaucoma eye drops [15]. Our case is the 
first reported case of CME associated with preservative 
free LP and in combination with the case reported by 
Sacchi et al. weakens the theory of preservative-induced 
CME [11].
Conclusions
We report a case of CME with SRD associated with LP 
administration with some interesting features. This is 
the first report of preservative free LP-induced CME. 
Furthermore, the CME occurred in an eye with a long 
standing pseudophakia after uncomplicated phacoemul-
sification. In our case no significant risk factor for CME 
development was recognized. Although the evidence 
for a causal association might be questioned and would 
be even more robust if CME recurred with rechallenge 
with LP, balancing the risk–benefit ratio we felt that it 
was unethical to rechallenge our patient in this setting 
because of the possibility of permanent visual loss [16]. 
The CME and SRD responded promptly to LP discon-
tinuation and nepafenac administration. This temporal 
association suggests a causal relationship between topical 
application of LP and CME in our patient. Interestingly, 
the presence of pre-treatment normal OCT enhances a 
causal relationship.
There is not a single medication or surgical treatment 
without potential adverse effects and complications. Our 
case indicates the possibility of unexpected events related 
Fig. 1 a Optical coherence tomography of right eye before latano-
prost administration. No pathology is detected. b Seven months 
after treatment with preservative free latanoprost optical coherence 
tomography in right eye revealed cystoid macular edema with 
well-defined, intraretinal cystic areas of low reflectivity in the macula 
with serous retinal detachment. c Two months after latanoprost dis-
continuation optical coherence tomography demonstrated complete 
resolution of cystoid macular edema. A subtle epiretinal membrane 
is noted
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to LP administration after uncomplicated cataract sur-
gery even in patients without any apparent risk factors.
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